Looks to me like the DEP Docetaxel monotherapy trial has not been as successful as hoped (no surprise there) and so they have held off reporting until DEP Doc + Gemcitabine results become available (and which are hopefully more positive).
“During the quarter, Starpharma completed recruitment in the DEP® docetaxel and gemcitabine combination arm of its Phase 2 DEP® docetaxel trial. As recruitment across all trial cohorts has now completed, Starpharma expects to report the final combined Phase 2 results in Q2 FY24.“
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-19
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
